Autoimmune-Rheum Dz (AIRD) flares occur in 10% w/ COVID vaccination, esp in pts w/ comorbidities, autoimmune morbidities & mental health disorders & Moderna vaccine. 3453 AIRD pts who recv Vax 9.5-11.3% had clinical flares (Arthritis 62% & fatigue 59%) https://t.co/RCtQnA9vc9 https://t.co/G5cXukkpUB

• https://bit.ly/3nnYfBh

Anti-mesangial autoantibodies in IgA nephropathy IgA nephropathy (IgAN) is a kidney disorder characterized by the buildup of immunoglobin A (IgA) in the glomeruli, which are bundles of capillaries that filter blood in the kidney. https://t.co/owOoAMrtxW https://t.co/RZMGkagcWJ

• https://bit.ly/3lMgoIq

Tofacitinib May Reduce Interstitial Lung Disease Risk in RA Tofacitinib (Xeljanz) in patients with RA stood out among several other biologic and targeted sDMARDs when it came to the incidence of ILD, a retrospective cohort study showed. https://t.co/XKjuxLWAKH https://t.co/M7ri9AL2wH

• https://bit.ly/3Zm4Jxw

What to do about pre-clinical RA? Much like the recent ACR Convergence, RheumNow Live’s 2023 conference led with this year’s hot topic of rheumatoid arthritis and especially what to do regarding pre-clinical RA. https://t.co/k8LcTmlpZs https://t.co/NBBbi91Fbi

• https://bit.ly/40w6JVH

Our old friend, hydroxychloroquine Dr.Arnaud ( @Lupusreference ) took the time to review one of our oldest therapies: hydroxychloroquine. He outlined how the anti-malarial medication has efficacy and widespread usage in lupus. https://t.co/NJK7uJIqsV https://t.co/CQStRUUkUn

• https://bit.ly/3JOlxHQ

#RNL2023 Dr. Stanley Cohen: possible adverse effects of JAKi -Herpes zoster, other infections -Malignancy -Occasional cytopenias -LFTs (with DMARDs) -Incr Cr or CPK -Acne -Incr lipids -GI perf -VTE Which do you counsel with your patients? https://t.co/Ej0Rm2VFCk https://t.co/aiHGE1LsAr

• https://bit.ly/3ZbG12R

#RNL2023:Kevin Deane: Anti-CCP positive leads to a 20-30% risk for articular clinical RA within 3-5 years https://t.co/UvXfC2iIEp https://t.co/zBoMiyy056

• https://bit.ly/3JK6nn8

EULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). https://t.co/0fXUVv0sCR https://t.co/fT6iAOPOpc

• https://bit.ly/3Kagzqw

LRA announces the 2023 recipients of the Lupus Innovation Award during #NationalKidneyMonth as three of this year’s seven award recipients are studying issues that come with this too-common complication. 🧵1of2 https://t.co/VZL9qJu9kF

Updated AAV Treatment Recommendations AAV is a multi-organ disease, which can be complex and may vary from person to person. Types of AAV include GPA, microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). https://t.co/YCNGYZfSr1 https://t.co/MFs9ykm4fb

• https://bit.ly/3z4eBl1

Our old friend, hydroxychloroquine Dr.Arnaud ( @Lupusreference ) took the time to review one of our oldest therapies: hydroxychloroquine. He outlined how the anti-malarial medication has efficacy and widespread usage in lupus. https://t.co/hKFLg1sogJ https://t.co/OxnbwpWygF

• https://bit.ly/40b4Ptp

#RNL2023 Dr. Stanley Cohen: possible adverse effects of JAKi -Herpes zoster, other infections -Malignancy -Occasional cytopenias -LFTs (with DMARDs) -Incr Cr or CPK -Acne -Incr lipids -GI perf -VTE Which do you counsel with your patients? https://t.co/8bEEC6gt5Z https://t.co/Toy2DxnC4S

• https://bit.ly/3yWHKyB

Treat to target approach in PsA Systematic rev: 12-43% pts achieved target of very low disease activity or remission Pts and docs agree: remission is primary goal, but Low disease activity is acceptable alternative @DrLauraCoates at #RNL2023 https://t.co/XyXBAn82F1 https://t.co/W0nVdq6urq

• https://bit.ly/3LLlEXj